{{Drugbox
| verifiedrevid = 470628311
| IUPAC_name = 2-oxo-2-[(2''S'',4''S'')-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
| image = Valrubicin.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CDI|valrubicin}}
| MedlinePlus = a611021
| pregnancy_US = C
| legal_status = Rx-only
| routes_of_administration = Intravesical

<!--Pharmacokinetic data-->
| bioavailability = Negligible
| protein_bound = >99%
| metabolism = Negligible
| excretion = In urine

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 56124-62-0
| ATC_prefix = L01
| ATC_suffix = DB09
| PubChem = 454216
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00385
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 399974
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2C6NUM6878
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1096885

<!--Chemical data-->
| C=34 | H=36 | F=3 | N=1 | O=13 
| molecular_weight = 723.644 g/mol
| smiles = FC(F)(F)C(=O)N[C@@H]5[C@H](O)[C@@H](O[C@@H](O[C@@H]4c3c(O)c2C(=O)c1c(OC)cccc1C(=O)c2c(O)c3C[C@@](O)(C(=O)COC(=O)CCCC)C4)C5)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZOCKGBMQLCSHFP-KQRAQHLDSA-N
}}
'''Valrubicin''' (''N''-trifluoroacetyladriamycin-14-valerate, trade name '''Valstar''') is a [[chemotherapy]] [[medication|drug]] used to treat [[bladder cancer]]. Valrubicin is a semisynthetic analog of the [[anthracycline]] [[doxorubicin]], and is administered by infusion directly into the [[Urinary bladder|bladder]].

It was originally launched as Valstar in the U.S. in 1999 for [[intravesical]] therapy of [[Bacille Calmette-Gu√©rin]] (BCG)-refractory [[carcinoma in situ]] of the [[urinary bladder]] in patients in whom [[cystectomy]] would be associated with unacceptable [[morbidity]] or [[Mortality rate|mortality]]; however, it was voluntarily withdrawn in 2002 due to manufacturing issues.<ref>[http://www.fdanews.com/newsletter/article?articleId=103010&issueId=11203 "Manufacturing Issues Remain for Indevus' Valstar"], [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] News. The MQN Weekly Bulletin, Jan. 11, 2008</ref> Valstar was relaunched on September 3, 2009.<ref>{{cite press release |url=http://www.news-medical.net/news/20090903/Endo-Pharmaceuticals-launches-VALSTAR-for-treating-recurrent-carcinoma-in-situ-bladder-tumors.aspx |title=Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors |date=2009-09-03 |accessdate=2009-11-26}}</ref>

==Side effects==
*[[hematuria|Blood in urine]]
*[[Urinary incontinence|Incontinence]]
*[[dysuria|painful or difficult urination]]
*Unusually frequent urination

==References==
<references />

{{Chemotherapeutic agents}}

[[Category:Anthracyclines]]
[[Category:Topoisomerase inhibitors]]
[[Category:Trifluoromethyl compounds]]
[[Category:Acetamides]]
[[Category:Withdrawn drugs]]